EMAIL THIS PAGE TO A FRIEND

Voprosy virusologii

[Efficacy of anti-neuraminidase drugs application during and after an influenza pandemic].


PMID 23785758

Abstract

The emergent 2009 A(H1N1) pandemic brought into acute focus the problem of choosing the most effective anti-influenza drugs for successive influenza infection spreading control. Oseltamivir and zanamivir, influenza virus neuraminidase inhibitors (NAIs), were recommended by the WHO experts for the treatment and prevention of influenza, including that caused by pandemic strains. A major concern regarding the use of specific antiviral compounds is the emergence of the drug-resistant strains. Oseltamivir carboxylate and zanamivir IC50 values were equal to 0.3-5.2 microM for the most of A(H1N1)pdm09 pandemic strains and 1.6-8.6 microM for the strains of influenza B virus in cell-based ELISA assay (2009-2010 season). All the studied strains of influenza A(H1N1 ) pdm09 (151) and B (22) viruses were sensitive to NAIs (2009-2011 seasons). For the first time in Russia oseltamivir-resistant A(H1N1) pdm09 influenza virus was isolated from the patient on the 5th day of a treatment course of this drug.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

N7271 α(2→3) Neuraminidase from Streptococcus pneumoniae, buffered aqueous solution
N5521 α(2→3,6) Neuraminidase from Clostridium perfringens (C. welchii), recombinant, expressed in E. coli, buffered aqueous solution, ≥250 units/mg protein
N3786
α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, Proteomics Grade, suitable for MALDI-TOF MS
N8271 α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, recombinant, expressed in E. coli, buffered aqueous solution
N5254 Neuraminidase Agarose from Clostridium perfringens (C. welchii), Type VI-A, ammonium sulfate suspension
N2876
Neuraminidase from Clostridium perfringens (C. welchii), Suitable for manufacturing of diagnostic kits and reagents, Type V, lyophilized powder
N3001
Neuraminidase from Clostridium perfringens (C. welchii), Type VI, lyophilized powder, 6-10 units/mg protein (using 4MU-NANA), 2-5 units/mg protein (mucin)
N5631
Neuraminidase from Clostridium perfringens (C. welchii), Type VIII, lyophilized powder, 10-20 units/mg protein (using 4MU-NANA), 3.5-8.0 units/mg protein (mucin)
N2133
Neuraminidase from Clostridium perfringens (C. welchii), Type X, lyophilized powder, ≥50 units/mg protein (using 4MU-NANA)
N7885
Neuraminidase from Vibrio cholerae, Type III, buffered aqueous solution, 0.2 μm filtered, 1-5 units/mg protein (Lowry, using NAN-lactose)
N6514
Neuraminidase from Vibrio cholerae, Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)
72197
Neuraminidase from Vibrio cholerae, ≥1.5 U/mL, specific activity ≥1.5 U/mg protein